Aktienanalyse zu Novocure Ltd (NVCR)NVCRNovocure Ltd

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Novocure Ltd (NVCR) is a good buy right now, trading at $17.82 with a recent RSI of 57.44 indicating bullish momentum. The company reported a Q2 revenue of $183.6 million, a 16% year-over-year increase, and raised its full-year revenue guidance to $710 million-$725 million. The stock has shown a 20.08% increase over the last 20 days, reflecting strong market sentiment and growth potential. However, the main risk is the negative net income reported at -$15.66 million in Q2 2026, which indicates ongoing financial challenges that investors should monitor closely.

6 analysts cover NVCR: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 23.58.